The FDA has approved Medtronic's U.S. launch of the OsteoCool Ablation System.
Here are five highlights:
1. The OsteoCool System is the only cooled radiofrequency ablation technology that offers simultaneous, dual-probe capabilities, providing procedural flexibility and predictable, customized treatment.
2. Cooled RF ablation uses targeted high-frequency energy to destroy cancer cells.
3. This device can be used on patients with painful spine metastases.
4. Metastatic bone disease has been reported to occur in 60 percent to 80 percent of cancer patients, most frequently among patients with primary malignancies of the breast, prostate, liver and lung.
5. Seventy percent of metastatic bone cancer patients develop at least one lesion in the spine.